Large-scale datasets generated via high-throughput sequencing and multi-omics technologies are shaping how researchers uncover features of cancer biology. The National Cancer Institute's (NCI) Proteomic Data Commons (PDC), a component of the Cancer Research...
COVID-19 is an emerging, rapidly evolving siituation.
What people with cancer should know: https://www.cancer.gov/coronavirus
Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers
Get the latest public health information from CDC: https://www.coronavirus.gov
Get the latest research information from NIH: https://www.nih.gov/coronavirus
News and Announcements
September 30, 2024
Single-cell proteomics (SCP) is enabling researchers to understand cancer progression, immune response, developmental pathways, and more all at the cellular level. Historically, SCP has represented a considerable challenge for researchers due to low amounts of proteins within a single cell and the,...
September 13, 2024
The National Cancer Institute's Proteomic Data Commons (PDC) launched in 2020, part of the National Cancer Institute's Cancer Research Data Commons (CRDC) data ecosystem, is the largest public repository of comprehensive tumor proteomic datasets, housing diverse data types such as proteome,...
August 21, 2024
Cancer immunotherapies hold promise for inducing durable responses across cancer types, yet their effectiveness varies significantly among patients. In an effort to deepen our understanding of the mechanisms underlying response and resistance to immunotherapy, CPTAC researchers from the Fred...
August 5, 2024
The following is the sixth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss bioinformatics, proteogenomics, and research ethics with Fernanda Martins Rodrigues, PhD, a post-doctoral research...
July 16, 2024
Despite improvements in detection and therapy, the prognosis for high-grade glioma (HGG) remains poor. Prior research has studied disease progression in HGG, but our understanding of how and why the disease recurs so often (>90% of patients within two years for the most aggressive HGG) remains...
June 26, 2024
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) has performed proteogenomic characterization for over 1,000 primary tumors spanning 10 cancer types: breast invasive carcinoma (BRCA), clear cell renal cell carcinoma (CCRCC), colon adenocarcinoma (COAD), glioblastoma (GBM), head and neck...
June 3, 2024
The following is the fifth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of glycoproteomics research with Tung-Shing Mamie Lih, PhD, an associate researcher at Johns Hopkins...
May 7, 2024
In a recent study aiming to address knowledge gaps in non-clear cell renal cell carcinoma (non-ccRCC), researchers from the National Cancer Institute's Clinical Proteomic Tumor Analysis Consortium (CPTAC) conducted an integrated multi-omic analysis of 48 non-ccRCC cases along with a previously...
April 25, 2024
The following is the fourth entry in a Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteogenomics research with Yifat Geffen, PhD, a postdoctoral researcher at the Broad Institute of MIT...
April 4, 2024
Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis despite advancements in treatment and diagnosis. Tumor recurrence, developing in most patients (>90%), poses a major challenge due to tumor heterogeneity and limited understanding of post-treatment evolution. Previous studies have...
March 29, 2024
The Clinical Proteomic Tumor Analysis Consortium (CPTAC) recently held its Scientific Investigator Meeting in Portland, Oregon at the Oregon Health & Science University campus. The meeting featured key scientific and programmatic updates spanning multiple cancer types presented by consortium...
March 20, 2024
The following is the third entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Nicole Tignor, PhD, Assistant Professor at the Icahn School of Medicine at...
February 23, 2024
Small cell lung cancer (SCLC) is an aggressive form of lung malignancy with historically poor prognoses and limited options for targeted treatment. The low availability of suitable biospecimens has also hampered large molecular characterization efforts.
February 14, 2024
The tumor microenvironment (TME) is a complex network which plays a crucial role in cancer progression and treatment responses. In a recently published Pan Cancer analysis, the Clinical Proteomic Tumor Analysis...
January 22, 2024
Acute Myeloid Leukemia (AML) is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. AML is known for its heterogeneity, presenting challenges in treatment and predicting patient outcomes.
January 8, 2024
The following is the second entry in a new Q&A series highlighting selected Clinical Proteomic Tumor Analysis Consortium (CPTAC) researchers and their work. Join us as we discuss multiple facets of proteomics research with Jeffrey Whitaker, PhD, Director of Proteomics within the Paulovich Lab at...